Iván Márquez-Rodas

21PUBLICATIONS
129CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyNanomedicineEpidemiological modellingPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|Jul 27, 2025
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Pablo Ayala-de Miguel, Eva Muñoz-Couselo, Lourdes Gutiérrez-Sanz

|Jun 27, 2025
BO-112 Plus Pembrolizumab for Patients With Anti-PD-1-Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203.

Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag

|Nov 09, 2024
Adjuvant Use of Pembrolizumab for Stage III Melanoma in a Real-World Setting in Europe.

Michael Weichenthal, Joanna Mangana, Iva Gavrilova

|Nov 06, 2024
Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.

Georgina V Long, James Larkin, Dirk Schadendorf

|Aug 05, 2024
Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.

Jeffrey Weber, Michele Del Vecchio, Mario Mandalá

Pageof 4

Frequent Collaborators

5 joint publications

Paolo Antonio Ascierto

4 joint publications

Mario Mandala

4 joint publications

Georgina V Long

4 joint publications

James Larkin